The last two trial updates have murdered the stock, and the Alzheimer's data won't be in for, what, another year? Seems like dead money and a company that can't seem to land a good trial. Although, this drug was a longshot, so 11% seems a little overdone.
yeah, this has nothing to do with the strength of UA's business, at all. lowered guidance in this case indicates nothing about the actual company.
some serious illegal #$%$ going on here.
And MYL should have taken the TEVA buyout 100% higher. what a bunch of #$%$ management teams.
I bought yesterday too. never been in this one before, but the drop seemed to be way worse than the news. put in a super-tight stop though...
seriously anemic volume n good news. hard to picture the rally lasting.